Steered by a prestigious Committee, the MedFIT conference programme brings together bright minds to discuss the latest trends in MedTech, diagnostic and digital health, to debate on innovation-driven topics, to foster learning and provoke conversations that matter. International experts will address current industry issues related to collaboration, financing, market access and regulation as well as MedTech digitalisation.

The recording of the MedFIT conferences will be available online from September 28th and for 30 days afterwards!

PLENARY SESSION

DAY 1 – Tuesday, September 20th

11:00 am – 12:30 pm CET

It’s all about data: Unlocking the value of MedTech data to fuel healthcare innovation

Building a connected health system and moving towards more preventive medicine requires good use of data. However, the challenges of harnessing the value of health data remain numerous, hindering its use for timely decision making: the volume of data is enormous, as is the speed at which it is generated, and its sources are increasingly varied. Ensuring the veracity of the data and optimising its value is now essential to improve clinical decision-making and fuel tomorrow’s innovation.


This plenary session will explore the business models around health data exploitation and how MedTech innovators can leverage it to differentiate themselves. What are the limitations and constraints that most organisations need to consider when using it? Which legal measures are appropriate to protect critical research data? What are the most pressing barriers to data connectivity? How to strike a balance between unlocking data and securing it, especially for user-generated data? What is to be expected from the newly launched European Health Data Space?

Moderator: Thomas Hagemeijer, Healthcare Lead, TLGG Consulting

TRACK 1: COLLABORATE TO INNOVATE

Fostering new collaborations is key to fuelling innovation and supporting R&D needs in MedTech. As global healthcare evolves to deliver more value to patients, partnerships with hospital leaders, technology experts, payers and innovators are the cornerstone of the medical technologies’ evolution. What are the elements to forgather to merge the scientific, academic, and industry spheres? How is innovation sourced through collaboration with academia? What are the main drivers and favoured models for big players/early-stage companies’ partnerships?

DAY 1 – Tuesday, September 20th

3:15 – 4:30 pm CET

How do Big MedTech balance between collaboration, co-development, and licensing to access early-stage technologies?

Many large medical device companies are now looking externally for new research and development activities by partnering with early stage MedTech companies or Academia. While this may seem riskier, it is now a key way to complement their extensive product portfolio and to meet the growing valuation of potential acquisitions. What are the criteria that drive large MedTech companies to focus either on co-development or licensing? What kind of players are their partner of choice for external innovation? What are the pros and cons of the different approaches? Are there preferred areas (indications, products, families of technology) for these types of collaborations and why?

Moderator: Suzanne Elvidge, Freelance writer, Biopharma, Healthcare, Business

  • Delphine Le Louet, Senior Financial analyst – European Healthcare, Biotech & Medtech, Société Générale
  • Antonio Sánchez-Cordero, Worldwide Vice President, Business Development (M&A), Peripheral Intervention, BD
DAY 2 – Wednesday, September 21st

10:30 – 11:30 am CET

Does the digital trend open new partnering and collaboration models between Start-ups/SMEs and Corporate?

In the age of digital health, strategic collaboration has become more important than ever, but it has also perhaps become more complex as we move from product-based to solution-based innovations. On what basis are start-up/company partnerships built today? What is the geometry and how are they conducted? How can these collaborations be early built to evolve towards other applications and future revenue streams? Who are the new players at the negotiating table? What are the challenges in building these partnerships and how can they be overcome?

  • Sheena Pirbhai, Founder & CEO, Stress Point Health

2:00 – 3:30 pm CET

Creating synergy between start-ups and hospitals: Latest challenges and opportunities in delivering innovative ideas and practices

Over the last two years, hospitals have had to face an unprecedented situation that has profoundly impacted the organisation of care in institutions and the working methods of health professionals. This transformation opens new paths of collaborations to meet the changing challenges of innovation and opportunities for start-ups to develop novel solutions. How are these collaborations built? What are the prospects and concrete examples of accelerated clinical applications? To what extent do these synergies enable the refinement and testing of solutions to best meet the needs and daily practices of healthcare providers?

Moderator: Tobias Silberzahn, Partner, McKinsey & Company and Host,Global Health Tech Network

TRACK 2: FINANCING INNOVATION

Seed and Series A investments are crucial to transforming new ideas into products and moving start-up teams into small businesses. Finding the right funding sources and equity partners to get from early stage to regulatory approval is far from straightforward. How to identify the initial sources of funding for MedTech R&D projects? What method should you use to fund your start-up? How to attract ventures for early-stage financing?

DAY 1 – Tuesday, September 20th

9:00 – 10:30 am CET

Make your first round count: Preparing alternative options to minimise dilution and optimise the size of your financing round

Your funding strategy goes hand in hand with your business strategy in the early stages of your innovation’s development. It is also crucial to understand how dilution may affect your start-up and to consider alternative financing options. What do you need to consider to find the right balance between dilution and the funds you need to raise? What type of funding and which investors are essential to make it work in the early days? How can your investors also be a resource for your business at the operational level? How can you make the best fundraising decisions to move your business forward and ensure that you have explored all options in a time-sensitive context?

Moderator: Jorge Juan Fernández García, Venture Partner, Nina Capital

5:00 – 6:15 pm CET

Diagnostic financing is on the rise: What is attracting investors?

The COVID-19 pandemic has raised awareness of the importance of point-of-care diagnostics and provided an opportunity to rethink and nurture the diagnostic industry. As the pandemic seems to subside, will the interest in IVD diagnostics and more broadly in traditional diagnostic tools persist? More specifically, what types of diagnostics and innovations are attracting early-stage investors today? What are the most pressing unmet needs and what are the major investment trends expected in the coming years for diagnostics? What is the risk/reward ratio for diagnostic technologies?

DAY 2 – Wednesday, Setpember 21st

11:45 am – 12:30 pm CET

What is driving the evolution of the investor profile in MedTech?

MedTech and diagnostic sectors are fast changing with rising digital medical-grade solutions and the expansion of consumer healthcare, creating new sources of innovations and investment opportunities. How is this impacting the landscape for venture capital investment in MedTech in 2022? How are the interest and profile of the early-stage investors evolving through the continuum of MedTech, digital health and consumer healthcare? How are investment strategies diversifying with the emergence of new sources of innovations?

Moderator: Arezki Yaiche, Head of Coverage France & Benelux, Acuris 

TRACK 3: INNOVATION TO MARKET

Planning a market access should start early in the product development process, increasing the chances of successfully bringing an innovation to market. How to keep track of market trends and regulatory requirements while building your strategy? How can a company accurately anticipate market access, pricing and reimbursement related issues? This track aims to give a comprehensive approach to the pathway to market for emerging medical technologies.

DAY 1 – Tuesday, September 20th

2:00 – 3:00 pm CET

Innovators’ checklist for successful market

A go-to-market strategy for MedTech start-up includes a multitude of elements, from regulatory pathway, business and reimbursement models, choice of the first market and commercialisation strategy and much more. As innovators find themselves looking to check all of the boxes on their journey to market, we have asked experienced experienced entrepreneurs and advisors to share their do’s and don’ts for a successful market access strategy.

Moderator: Arthur Olesch, Founder & Editor-in-Chief, about Digital Health

DAY 2 – Wednesday, September 21st

9:00 – 10:00 am CET

How to define your business model while navigating the interconnection between various regulatory frameworks?

The years 2021 and 2022 have been intense in terms of regulation for the MedTech sector in Europe, including the implementation of the MDR and IVDR, the advancement of Health Technology Assessment and the proposed EU AI Act. How can MedTech innovators navigate this complex regulatory framework and integrate it in their strategic development? What is the impact on the business model and the cost of the innovation process for small players at early stage? How can regulation be leveraged to be more used as a guide and not only as a constraint?

Moderator: Hugh HarveyManaging Director, Hardian Health

4:00 – 5:30 pm CET

Exploring how health economics can be leveraged to support market access for early-stage start-ups

Health-economic analyses play a key role during the market access trajectory, as they quantify the added value of a product or service. How can health economic models support MedTech innovations to demonstrate value, achieve market access and reach more patients? On what basis should health-economic arguments be built? How can they provide compelling arguments for investors, regulatory agencies or other relevant stakeholders?